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Abstract
Background: Hepatitis E virus (HEV) infection is an important cause of acute hepatitis worldwide. In pregnant
women, HEV can cause more severe symptoms, with high rates of fatal hepatic failure in endemic countries.
However, HEV prevalence and circulation among pregnant women from South America is almost unknown. We
aimed to investigate HEV infection in pregnant women for the first time in Argentina.
Methods: IgG and IgM anti-HEV antibodies and RNA-HEV were investigated (by ELISA assays and RT-Nested-PCR,
respectively) in 202 serum samples from pregnant women collected in the central region of Argentina between
2015 and 2017. A control group of 155 non-pregnant women was included (year 2018).
Results: The IgG anti-HEV positivity rate was 8.4% (17/202), higher than the 2.6% (4/155) obtained for the non-
pregnant women control group, and showing association between pregnancy and HEV infection (p = 0.023, OR =
3.5, CI95% = 1.1–10.5). Women younger than 25 years old presented higher levels of antibodies, and there were no
differences in the prevalences between trimesters of pregnancy. Two samples were reactive for IgM anti-HEV,
showing recent infections, although no symptoms were registered in these patients. All samples were negative for
RNA-HEV amplification.
Conclusions: HEV produces infections in pregnant women from Argentina, alerting health teams to consider it as a
possible cause of liver disease.
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Background
The hepatitis E virus (HEV) (specie Orthohepevirus A,
genus Ortohepevirus, family Hepeviridae) is an important
pathogen of worldwide distribution, causing acute hepatitis,
transmitted mainly by the fecal-oral route [1, 2]. HEV is a
non-enveloped virus with a positive sense single stranded
RNA genome. According to its genetic variability, it has
been classified into 8 genotypes [1–8], from which 5 of
them can infect humans (1 to 4 and 7) [1, 3].
Clinical presentations of HEV infection are varied: im-
munocompetent individuals can develop asymptomatic
or mild infections, while immunocompromised patients,
pregnant women, transplant patients or those with
underlying liver problems can lead more severe illnesses,
including fulminant hepatic failure (FHF) and chronic
disease [4]. Particularly in pregnant women, severe acute
liver disease and progression to FHF have been regis-
tered when the infecting genotype is 1, which may result
in fetal and/or maternal mortality, abortion or prema-
ture delivery [5]. Because of this, pregnant women have
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attracted more attention regarding HEV infection,
mainly in endemic regions, where seropositivity rates in
this group of patients reach values as high as 68% [4].
In South America, there are very few studies about
HEV detection in pregnant women, performed in
Venezuela and Brazil in the 1990’s decade, which report
IgG anti-HEV seroprevalences of 1.0, 1.3 and 1.9% [6, 7].
After several years, a study from Brazil reported a much
higher prevalence of 19% in the pregnant women group,
showing no significant differences with blood donors
from the same region [8].
In Argentina, acute hepatitis E cases are reported spor-
adically. HEV-RNA genotype 3 (HEV-3) detections have
been performed in pigs and environmental samples, and
two chronic cases were documented [9]. Strikingly, an
acute hepatitis E case in a 41 years old woman, who had
had a spontaneous abortion a month before onset of
symptoms, was registered in Mendoza province, at the
West region of the country [Bussetti et al. 2017, personal
communication]. Despite this background, there are no
epidemiological studies about HEV in pregnant women
in Argentina. Having data about the circulation of HEV
in this population would contribute to the knowledge
and to provide appropriate public health recommenda-
tions in our region. For this reason, we aimed to investi-
gate the local circulation of HEV in this group of
patients.
Methods
This is an anonymous, descriptive, retrospective, non-
interventionist study in which 202 serum samples from
pregnant women (median age: 30 years; range: 18–43
years) collected and stored in 2 health centres from Cór-
doba (central region of Argentina) between 2015 and
2017, were analysed for IgG and IgM anti-HEV detec-
tion by ELISA assays (Diapro, Italy; diagnostic specificity
≥98%, diagnostic sensitivity ≥98%). Positive samples were
tested for HEV-RNA amplification by RT-Nested PCR,
amplifying a 348 bp fragment of the ORF-2 region [10].
Only the following data were available: date of sampling,
age, neighbourhood and trimester of pregnancy.
Additionally, 155 serum samples from non-pregnant
women who attended health care centres from Córdoba
city for a routine control during April and May 2018
were retrospectively analysed as a control group.
Prevalences were expressed as percentages. To assess
the association between individual variables and IgG
anti-HEV, we used independent t or chi-square tests.
Exact 95% confidence intervals (CIs) were utilized. Stat-
istical significance was defined at p < 0.05. The statistical
package Stata 13.0 was used.
This study was approved by the Training and teaching
Committee of the Hospital Rawson and the Ethics Com-
mittee of the Hospital Privado Universitario de Córdoba
(protocol HP 4–281), in accordance to the specifications
of the Ministry of Health of the Province of Córdoba,
Argentina (Law N°9694). Since this was a retrospective
study, informed consent was not required.
Results
A total of 202 serum samples from pregnant women
were analysed for HEV. The global IgG anti-HEV preva-
lence obtained in this population was 8.4% (17/202),
higher than the 2.6% obtained in the control group (4/
155) (p = 0.023). Statistical association between preg-
nancy and HEV infection was found (OR = 3.5, CI95%:
1.1–10.5). Distribution of the positive samples among
and around the city was homogeneous, without a distri-
bution pattern (Fig. 1), and no significant difference was
observed in the HEV seroprevalence according to the
neighbourhood. Although the prevalence was higher in
the second trimester (14%), this difference was not sta-
tistically significant (p = 0.42) (Table 1). When dividing
the samples into group ages, surprisingly, the ≤25 years
old group showed the higher seropositivity value (16.7%,
p = 0.032) (Table 1), showing statistical association be-
tween low age of pregnancy (≤25 years old) and HEV
seroprevalence (OR = 3.2, CI95%: 1.2–8.9). No significant
difference was found in the HEV seroprevalence when
analysing the samples according to the studied years.
From the 17 positive samples for IgG anti-HEV, 2
were reactive for IgM anti-HEV, evidencing acute (re-
cent) infections. One of them, belonged to a 36 years old
patient in the second trimester of pregnancy, with pork
and fish consumption habits less than once a week,
without history of transfusions (in this case epidemio-
logical data could be obtained); while the other IgM
positive sample belonged to a 18 years old patient in the
first trimester of pregnancy, with no other available data.
These samples resulted negative for HEV-RNA amplifi-
cation. None of these patients had a history of symptom-
atic acute hepatitis, so mild or sub-clinical infections
would have occurred.
Discussion
HEV is known to produce acute hepatitis worldwide,
with some complications in co-morbidity patients. In
pregnant women, fatality rates are increased in endemic
regions, being as high as 20–30% [11]. This may be re-
lated to several possible factors, such as differences in
immune and humoral factors occurring during preg-
nancy, the genetic and environmental factors with its
occurrence in certain developing countries, and the in-
fecting HEV genotype [12].
In South America the overall epidemiology of HEV
has been little studied, and the burden of the disease re-
mains largely unknown [9]. There are very few studies
about HEV detection in pregnant women, most of them
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performed in the 1990’s decade (IgG anti-HEV seropre-
valences of 1.0, 1.3 and 1.9%) [6, 7]. Our results show,
for the first time, a HEV seropositivity rate of 8.4% in
pregnant women from Argentina, similar to the preva-
lences found in developed countries for the same popu-
lation, such as France (7.7%) [13], but showing a great
difference with a recent Brazilian seroprevalence value of
19% [8]. This could be due to many reasons: differences
in the HEV local circulations, the level of public health
and hygiene of each region [4], and the kit utilized for
the HEV antibody detection, since Wantai kit (used in
the Brazilian study) has been reported to be more sensi-
tive [9, 14], yielding higher seroprevalence values. We
found a higher HEV prevalence in pregnant women than
the control group (non-pregnant women, 2.6%), as well
as than general population in the same region, which
has been previously reported to be 4% [10]. This could
be a consequence of the decrease in some of the im-
mune responses during pregnancy [15], together with
hormonal changes [12] (increase of steroid hormones),
Fig. 1 Map showing the geographical location of the samples analyzed during this study in Córdoba province, Argentina. The blue bullets
indicate the location of the negative anti-HEV IgG samples, while the red bullets indicate the location of the positive anti-HEV IgG samples. The
image of the map was taken from Pinterest, under written consent from the author
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which facilitates a scenario prone to infections (and
higher levels of antibodies). It would be important to ob-
tain data of HEV circulation in pregnant women from
other regions of our country, since there could be varia-
tions in seropositivity rates among different geographical
regions, which reflect differences in the status of public
health and hygiene, risk factors, and routes of transmis-
sion, as reported in other countries [16].
When dividing the samples into group ages, surpris-
ingly, the group ≤25 years old had the highest seroposi-
tivity rate. This is contrary to what we expected and
other studies have reported: that seroprevalence in-
creases with age, probably due to more exposure to the
virus [4, 5, 10]. One explanation for our results could be
that women belonging to the ≤25 years old group came
from low income neighbourhoods, which could indicate
poor sanitary conditions and an increased viral transmis-
sion. It would be necessary to analyse a higher number
of samples belonging to different neighbourhoods (with
different income levels) to achieve a conclusion regard-
ing an association between the age of the patients and
the HEV serostatus.
We demonstrated the presence of acute infections
during pregnancy in Argentina (individuals with positive
IgM anti-HEV), showing viral circulation among this
group of patients. The absence of risk factors in one of
the positive samples (such as consumption of pork or
fish, contact with pigs, transfusions) would reveal alter-
native routes of transmission, such as contact with water
contaminated with the virus, taking into account that
HEV has been detected in local recreational aqueous
matrices [17].
Unfortunately, RNA-HEV could not be amplified in
any sample, so the infecting genotype could not be de-
termined. It is known that HEV genotype 3 (HEV-3) cir-
culates in Argentina [9], so it is possible that this
genotype would be the responsible for infections in the
pregnant women studied. This could be a reason for the
occurrence of asymptomatic infections, since severe
hepatitis and FHF cases have been reported as a conse-
quence of HEV genotype 1 (HEV-1) infections in other
parts of the world [12]. However, it is important to con-
tinue monitoring acute liver diseases in this population
due to the detections of HEV-1 reported in the border-
ing country of Uruguay [18, 19]. This situation would
lead to the entrance of HEV-1 to Argentina (from
Uruguay), or to the HEV-1 infection of Argentine preg-
nant women who visit Uruguay (the Uruguayan coasts
are a holiday destination for many Argentine people).
Conclusions
Our results show that HEV produces infections in preg-
nant women in Argentina, alerting physicians as a pos-
sible cause of hepatitis in this population. A close
follow-up in pregnant women should be necessary to
prevent HEV infections, as well as to early detect severe
infections in our country.
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Table 1 Number of samples analysed, IgG-anti HEV positive samples and seropositivity rates obtained in pregnant women from
Argentina according to the variables analysed
Variable N° samples analysed N° IgG anti-HEV positive samples HEV seropositivity (%) P-value
Age (in years) ≤25 48 8 16.7% p = 0.032*
26–35 112 6 5.4%
≥36 42 2 4.8%
Trimester of pregnancya 1st 75 6 8.0% p = 0.421
2nd 57 8 14.0%
3rd 65 3 4.6%
aThis data was not available in 5 samples
*Statistically significant difference
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